Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Pharmaceutical Preparations · market cap $1.2B
Research and calibrated estimates, not financial advice — verify before acting.
| Asset | Phase | Indication |
|---|---|---|
| Technosphere Insulin Inhalation Powder | Phase 2 | Diabetes Type 2 |
| Active comparator | Phase 3 | Diabetes, Type I |
| Technosphere/Insulin | Phase 2 | Diabetes Mellitus, Type 2 |
| Technosphere Insulin | Phase 3 | Type 2 Diabetes Mellitus |
| 70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin) | Phase 3 | Diabetes Type 2 |
| Actrapid | Phase 2 | Type 2 Diabetes Mellitus |
| MKC1106-MT | Phase 2 | Melanoma (Skin) |
| Afrezza | Phase 3 | Diabetes Mellitus, Type 1 |
| Metformin & Secretagogues | Phase 3 | Diabetes Mellitus, Type 2 |
| Technosphere® Insulin with MedTone C Inhaler | Phase 3 | Type 1 Diabetes Mellitus |
| Usual Care | Phase 3 | Diabetes, Type 1 |
| Technosphere® Insulin Inhalation Powder and MedTone™ Inhaler | Phase 2 | Type 2 Diabetes Mellitus |
| Technosphere® Insulin | Phase 3 | Type 2 Diabetes |
| Technosphere® Insulin Inhalation Powder | Phase 2 | Diabetes Mellitus: Type 1 |
| Basal insulin | Phase 2 | Type 1 Diabetes Mellitus |
Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
See ProApproval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.